Einzeltreffer — DigiBib

Objective: To compare the value of fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) and magnetic resonance imaging (MRI) in differentiating benign and malignant ovarian or adnexal tumors.

Materials and Methods: English articles reporting on the diagnostic performance of MRI or 18 F-FDG PET/CT in identifying benign and malignant ovarian or adnexal tumors published in PubMed and Embase between January 2000 and January 2021 were included in the meta-analysis. Two authors independently extracted the data. If the data presented in the study report could be used to construct a 2 × 2 contingency table comparing 18 F-FDG PET/CT and MRI, the studies were selected for the analysis. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used to evaluate the quality of the included studies. Forest plots were generated according to the sensitivity and specificity of 18 F-FDG PET/CT and MRI.

Results: A total of 27 articles, including 11 18 F-FDG PET/CT studies and 17 MRI studies on the differentiation of benign and malignant ovarian or adnexal tumors, were included in this meta-analysis. The pooled sensitivity and specificity for 18 F-FDG PET/CT in differentiating benign and malignant ovarian or adnexal tumors were 0.94 (95% CI, 0.87-0.97) and 0.86 (95% CI, 0.79-0.91), respectively, and the pooled sensitivity and specificity for MRI were 0.92 (95% CI: 0.89-0.95) and 0.85 (95% CI: 0.79-0.89), respectively.

Conclusion: While MRI and 18 F-FDG PET/CT both showed to have high and similar diagnostic performance in the differential diagnosis of benign and malignant ovarian or adnexal tumors, MRI, a promising non-radiation imaging technology, may be a more suitable choice for patients with ovarian or accessory tumors. Nonetheless, prospective studies directly comparing MRI and 18F-FDG PET/CT diagnostic performance in the differentiation of benign and malignant ovarian or adnexal tumors are needed.

Titel:	Indirect comparison of the diagnostic performance of <superscript>18</superscript> F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.
Autor/in / Beteiligte Person:	Hu, X ; Li, D ; Liang, Z ; Liao, Y ; Yang, L ; Wang, R ; Wang, P ; Cai, J
Link:	Full Text Finder (Volltext)
Zeitschrift:	BMC cancer, Jg. 21 (2021-10-06), Heft 1, S. 1080
Veröffentlichung:	London : BioMed Central, [2001-, 2021
Medientyp:	academicJournal
ISSN:	1471-2407 (electronic)
DOI:	10.1186/s12885-021-08815-3
Schlagwort:	Adnexal Diseases diagnostic imaging Adult Diagnosis, Differential Female Humans Middle Aged Publication Bias Sensitivity and Specificity Fluorodeoxyglucose F18 Magnetic Resonance Imaging Ovarian Neoplasms diagnostic imaging Positron Emission Tomography Computed Tomography Radiopharmaceuticals
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Meta-Analysis; Systematic Review Language: English [BMC Cancer] 2021 Oct 06; Vol. 21 (1), pp. 1080. <i>Date of Electronic Publication: </i>2021 Oct 06. MeSH Terms: Fluorodeoxyglucose F18* ; Magnetic Resonance Imaging* ; Positron Emission Tomography Computed Tomography* ; Radiopharmaceuticals* ; Ovarian Neoplasms / *diagnostic imaging ; Adnexal Diseases / diagnostic imaging ; Adult ; Diagnosis, Differential ; Female ; Humans ; Middle Aged ; Publication Bias ; Sensitivity and Specificity References: AJR Am J Roentgenol. 2003 May;180(5):1297-304. (PMID: 12704041) ; Gynecol Oncol. 2007 Apr;105(1):145-9. (PMID: 17229460) ; J Magn Reson Imaging. 2013 Jan;37(1):164-71. (PMID: 23188749) ; Int J Gynecol Cancer. 2007 Jan-Feb;17(1):61-7. (PMID: 17291233) ; Am J Pathol. 2016 Apr;186(4):733-47. (PMID: 27012190) ; Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):902-12. (PMID: 18381473) ; Lancet. 1994 Nov 5;344(8932):1250-4. (PMID: 7967985) ; Clin Nucl Med. 2015 Feb;40(2):97-102. (PMID: 25546187) ; Abdom Imaging. 2012 Oct;37(5):897-903. (PMID: 22038329) ; J Clin Epidemiol. 2005 Sep;58(9):882-93. (PMID: 16085191) ; Eur Radiol. 2019 Jul;29(7):3358-3371. (PMID: 30963272) ; Magn Reson Med Sci. 2012;11(3):171-8. (PMID: 23037561) ; Cancer. 2007 May 1;109(9):1887-96. (PMID: 17373668) ; Cancer Manag Res. 2018 May 22;10:1313-1318. (PMID: 29861641) ; Am J Epidemiol. 2010 Jan 1;171(1):45-53. (PMID: 19910378) ; Acta Radiol. 2013 Apr 1;54(3):340-8. (PMID: 23319725) ; Eur J Radiol. 2012 Aug;81(8):1917-25. (PMID: 21908120) ; PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072) ; Int J Gynecol Cancer. 2014 Mar;24(3):454-60. (PMID: 24463640) ; Semin Nucl Med. 2019 Nov;49(6):484-492. (PMID: 31630732) ; Eur Radiol. 2014 Apr;24(4):889-901. (PMID: 24322510) ; Lancet. 2019 Mar 23;393(10177):1240-1253. (PMID: 30910306) ; Clin Cancer Res. 2016 Sep 15;22(18):4664-75. (PMID: 27060155) ; Nucl Med Commun. 2011 Jul;32(7):549-53. (PMID: 21407140) ; Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046) ; Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303. (PMID: 28639753) ; Ann Nucl Med. 2018 Dec;32(10):669-677. (PMID: 30101392) ; Nat Rev Cancer. 2010 Nov;10(11):803-8. (PMID: 20944665) ; J Comput Assist Tomogr. 2004 Jul-Aug;28(4):505-16. (PMID: 15232382) ; J Med Imaging Radiat Oncol. 2018 Feb 5;:. (PMID: 29399968) ; Radiology. 1982 Apr;143(1):157-68. (PMID: 7038763) ; J Obstet Gynaecol Res. 2017 Feb;43(2):378-386. (PMID: 28150407) ; Diagn Interv Radiol. 2018 Mar-Apr;24(2):63-71. (PMID: 29467113) ; Nucl Med Commun. 2007 Aug;28(8):589-95. (PMID: 17625380) ; Gynecol Oncol. 2010 Mar;116(3):389-94. (PMID: 19926121) ; PLoS Med. 2005 Mar;2(3):e70. (PMID: 15783258) ; Am J Epidemiol. 2010 Nov 15;172(10):1181-9. (PMID: 20861144) ; Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1902-12. (PMID: 22962405) ; Radiographics. 2006 Sep-Oct;26(5):1335-53. (PMID: 16973768) ; J Gynecol Oncol. 2018 Nov;29(6):e98. (PMID: 30207106) ; Eur J Cancer. 2017 Sep;83:88-98. (PMID: 28734146) ; Ann N Y Acad Sci. 2011 Jun;1228:1-18. (PMID: 21718318) ; Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):103-11. (PMID: 10667470) ; Cancer Causes Control. 2009 Apr;20(3):335-44. (PMID: 18941913) ; Prog Mol Biol Transl Sci. 2019;162:241-252. (PMID: 30905453) ; Diagn Interv Imaging. 2020 Mar;101(3):147-155. (PMID: 31987805) ; Radiologe. 2008 Apr;48(4):384-96. (PMID: 17891370) ; AJR Am J Roentgenol. 2017 Dec;209(6):W336-W349. (PMID: 28981354) ; Gynecol Oncol. 2013 Dec;131(3):694-700. (PMID: 23988417) ; Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1073-1079. (PMID: 31030476) ; Int J Clin Exp Med. 2015 Nov 15;8(11):19928-37. (PMID: 26884905) ; JAMA Netw Open. 2020 Jan 3;3(1):e1919896. (PMID: 31977064) ; CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) ; Ann Epidemiol. 2011 Mar;21(3):188-96. (PMID: 21109450) ; Int J Gynaecol Obstet. 2008 Aug;102(2):124-7. (PMID: 18423470) ; World J Surg Oncol. 2012 Nov 09;10:237. (PMID: 23137333) ; BJOG. 2008 Jun;115(7):894-901. (PMID: 18485169) ; Int J Clin Oncol. 2018 Jun;23(3):514-521. (PMID: 29236181) ; Am J Epidemiol. 2009 Sep 1;170(5):598-606. (PMID: 19605513) ; BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) Contributed Indexing: Keywords: Magnetic resonance imaging; Meta-analysis; Ovarian tumor; Positron emission tomography/computed tomography Substance Nomenclature: 0 (Radiopharmaceuticals) ; 0Z5B2CJX4D (Fluorodeoxyglucose F18) Entry Date(s): Date Created: 20211007 Date Completed: 20211019 Latest Revision: 20211019 Update Code: 20231215 PubMed Central ID: PMC8495994

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Indirect comparison of the diagnostic performance of <superscript>18</superscript> F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.